Coronary artery calcification happens when calcium and phosphate deposits build up in the walls of the arteries that supply blood to your heart. It’s not a simple buildup like limescale in a pipe. It’s an active biological process driven by the same cells and signals your body uses to build bone, but happening in the wrong place. The causes range from everyday risk factors like aging and high cholesterol to deeper metabolic imbalances, genetic predisposition, and chronic disease.
How Calcification Actually Develops
Your artery walls contain smooth muscle cells that normally help blood vessels contract and relax. Under certain conditions, these cells undergo a transformation: they start behaving like the bone-forming cells found in your skeleton. Once transformed, they begin depositing calcium and phosphate minerals into the artery wall, essentially creating small patches of bone-like tissue inside your blood vessels.
This process isn’t random. It’s driven by specific molecular signals. Tiny particles called vesicular microRNAs can switch on bone-building gene programs in nearby stem cells, pushing them to become calcifying cells. The type of calcification also matters. In the inner lining of arteries, where cholesterol plaques form, smooth muscle cells transform into cartilage-like cells that lay down hard mineral deposits. In the muscular middle layer of the artery wall, a different transformation occurs, one more closely tied to diabetes and metabolic disease, where cells take on a more directly bone-like character.
The Major Risk Factors
The most significant drivers of coronary artery calcification are the same factors behind heart disease more broadly: aging, high cholesterol, high blood pressure, smoking, and diabetes. But each contributes in a slightly different way.
Aging is the single strongest predictor. Among adults aged 30 to 45 with no symptoms, about 26% of white men already have detectable calcium in their coronary arteries. For white women in the same age range, that number is around 10%. By the time people reach their 60s and 70s, calcification is far more common. The process accelerates over decades as repeated exposure to cholesterol infiltration, inflammation, and cell turnover gives artery walls more opportunities to trigger that bone-forming switch.
High cholesterol and high blood pressure damage the inner lining of arteries, creating chronic low-grade inflammation. This inflammation is a key trigger for smooth muscle cells to change their identity and begin mineralizing. Diabetes accelerates calcification through multiple pathways, including direct effects on how cells handle calcium and phosphate, and by promoting the type of calcification that occurs in the muscular wall of arteries rather than just within plaques.
The Role of Calcium and Phosphate Balance
Calcification requires both elevated calcium and elevated phosphate in the local environment around artery cells. Research on arterial tissue shows that neither mineral alone is enough at normal concentrations. When both rise above certain thresholds, mineral deposits form. Of the two, calcium appears to be the more dominant trigger, with even modest increases tipping the balance toward calcification.
These minerals don’t just passively crystallize. They also activate biological programs inside smooth muscle cells, switching on enzymes and proteins associated with bone formation. This means the mineral environment doesn’t just allow calcification to happen physically; it actively reprograms cells to produce more of it. For most people with healthy kidneys, the body tightly controls blood levels of calcium and phosphate. But when that regulation breaks down, as it does in kidney disease, calcification accelerates dramatically.
Kidney Disease as an Accelerator
Chronic kidney disease is one of the most powerful accelerators of coronary artery calcification. The kidneys normally filter excess phosphate out of the blood, and when they fail, phosphate levels climb. At the same time, levels of parathyroid hormone and a bone-regulating signal called fibroblast growth factor 23 rise as the body tries to compensate. Vitamin D metabolism is disrupted. The result is a perfect storm of mineral imbalance.
There’s also a more direct connection between weakening bones and hardening arteries. In kidney disease, bone breaks down faster than it rebuilds, releasing calcium and phosphate into the bloodstream. Because the kidneys can no longer clear these minerals efficiently, they get redirected from the skeleton into artery walls and heart valves. This “mineral redirection hypothesis” helps explain why people with kidney disease develop calcification far earlier and more severely than the general population.
Vitamin K deficiency adds another layer. Your body produces a protein called matrix Gla protein (MGP) that acts as a natural brake on calcification in artery walls. But MGP only works when it’s activated by vitamin K. People with kidney disease are frequently deficient in vitamin K, which means their primary defense against arterial calcification is disabled at the very time their mineral levels are most dangerous.
Your Body’s Natural Defenses Against Calcification
Healthy arteries don’t calcify easily because the body has built-in inhibitors. Matrix Gla protein is one of the most important. When properly activated by vitamin K, it binds to calcium crystals forming in artery walls and prevents them from growing. In people with adequate vitamin K levels, this system works continuously to keep arteries flexible.
When vitamin K is deficient, MGP remains in its inactive form, and its protective effect is lost. Inactive MGP in the bloodstream is associated with higher rates of cardiovascular disease. This connection has prompted clinical research into whether vitamin K supplementation could slow or prevent vascular calcification, particularly in high-risk groups like dialysis patients.
Genetic Predisposition
Some people are genetically wired to calcify their arteries earlier. The most studied genetic region linked to coronary artery disease sits on chromosome 9 (the 9p21.3 locus), discovered in 2007 through large-scale genetic studies. This region, which is unique to primates, contains roughly 80 genetic variants that influence how smooth muscle cells in arteries behave.
Research using lab-grown artery cells shows that people carrying the risk version of this genetic region have smooth muscle cells that spontaneously shift toward a bone-forming state. Even without any calcification trigger, these cells deposit about twice as much calcium as cells without the risk variant. When exposed to calcification-promoting conditions, the difference grows further. These risk-carrying cells also migrate more slowly, meaning they’re less able to repair or remodel artery walls normally. The effect appears to work through a regulatory RNA molecule called ANRIL, which, when overexpressed, is enough on its own to activate the bone-forming program in artery cells.
The Statin Paradox
If you take a statin and get a calcium scan, your score may actually be higher than expected. This seems contradictory since statins reduce heart attack risk, but it reflects an important nuance in how calcification works.
Statins stabilize cholesterol-filled plaques by making them denser and less likely to rupture. Part of that stabilization process involves converting soft, vulnerable plaque into harder, calcified plaque. The calcium scan (which produces an Agatston score) weights density heavily, so denser plaques score higher even though they’re actually safer. A high calcium score in someone on a statin can mean either genuinely high-risk disease or highly stable plaques at relatively lower risk. The scan still has prognostic value in statin users, but interpreting it requires context about medication history.
What a Calcium Score Tells You
Coronary artery calcium is measured with a quick, non-contrast CT scan of the chest. No dye injection is needed. The scan produces an Agatston score calculated from the area and density of calcified plaques. Guidelines use three main categories to guide decisions about preventive treatment:
- Score of 0: Less than 5% chance of a major cardiovascular event over 10 years. This is highly reassuring and often means preventive medications like statins can be deferred.
- Score of 1 to 99: Roughly 5% to 9% ten-year risk. Calcification is present but limited.
- Score of 100 or higher: Greater than 13% ten-year risk. At this level, guidelines generally favor starting or intensifying preventive therapy.
A score of zero doesn’t guarantee you’ll never develop heart disease, but it’s one of the strongest negative predictors available. Conversely, a high score in a young person is a strong signal that risk factors need aggressive management, since it reflects years of subclinical disease that wouldn’t be caught by standard cholesterol testing alone.